Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPHATIC: PBT and Liver Transplant for Hilar Cholangiocarcinoma
NCT06434493Not yet recruiting
- Sponsor
- The Christie
- Start
- Nov 2024
- Primary completion
- Jun 2028
01
Overview
Open-label, single-arm trial, sponsored by The Christie. Primary endpoints: Incidence of Common Toxicity Criteria for recording Adverse Events (CTCAE) Grade 3 and above toxicity and Proportion of patients who undergo a successful liver transplant. Planned start Nov 2024; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06434493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434493.